Pharsight

1. List of Inrebic drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7528143	IMPACT	Bi-aryl meta-pyrimidine inhibitors of kinases	Dec, 2026 (3 years from now)
US7825246	IMPACT	Bi-aryl meta-pyrimidine inhibitors of kinases	Dec, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199	IMPACT	Use of bi-aryl meta-pyrimidine inhibitors of kinases	Jun, 2028 (5 years from now)
US10391094	IMPACT	Compositions and methods for treating myelofibrosis	Jun, 2032 (9 years from now)
US11400092	IMPACT	Methods of treating myeloproliferative disorders	Sep, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 16, 2026
New Chemical Entity Exclusivity (NCE)	Aug 16, 2024

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring...

Dosage: CAPSULE;ORAL